The role of cohort studies in drug development: Clinical evidence of antiviral activity of serotonin reuptake inhibitors and HMG-CoA reductase inhibitors in the central nervous system

Journal of Neuroimmune Pharmacology

Volumn 2, Issue 1, 2007, Pages 120-127

  Letendre, Scott L ^a,h   Marquie Beck, Jennifer ^a   Ellis, Ronald J ^a,g   Woods, Steven Paul ^a,i   Best, Brookie ^a   Clifford, David B ^b   Collier, Ann C ^c   Gelman, Benjamin B ^d,o   Marra, Christina ^c   McArthur, Justin C ^e   McCutchan, J Allen ^a,g   Morgello, Susan ^f   Simpson, David ^f   Alexander, Terry J ^a,g   Durelle, Janis ^a,h   Heaton, Robert ^a,i   Grant, Igor ^a   Marcotte, Thomas D ^p   Neumayer, Shondra ^p   Capparelli, Edmund ^h   Atkinson, J Hampton ⁱ   Franklin, Donald ⁱ   Wong, Joseph K ^j   Ignacio, Caroline ^j   Jernigan, Terry ^k   Taylor, Michael J ^k   Theilmann, Rebecca ^k   Gamst, Anthony C ^l   Cushman, Clint ^l   Frybarger, Michelle ^l   Abramson, Ian ^m   Lazzaretto, Deborah ^m   Von Jaeger, Rodney ⁿ   Al Lozi, Muhammad ^b   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^g Neuromedical Component

^h Laboratory Pharmacology and Immunology Component   (United States)

ⁱ Neurobehavioral Component

^j Virology Component

^k Imaging Component

^l Data Management Unit

^m Statistical Unit   (France)

ⁿ Protocol Coordinating Component

^o UNIVERSITY OF TEXAS   (United States)

^p Mount Sinai School of Medicine Site ^*

more..

Author keywords

Cerebrospinal fluid; HIV; Serotonin reuptake inhibitors; Statins

Indexed keywords

ANTIRETROVIRUS AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; DRUG DESIGN; DRUG EFFECT; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; PSYCHOLOGICAL ASPECT; SYNTHESIS; VIROLOGY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-RETROVIRAL AGENTS; CENTRAL NERVOUS SYSTEM; COHORT STUDIES; DRUG DESIGN; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS;

EID: 33846804487     PISSN: 15571890     EISSN: 15571904     Source Type: Journal    
DOI: 10.1007/s11481-006-9054-y     Document Type: Article

References (46)

1. Ances B, Letendre S, Buzzell M, Marquie-Beck J, Lazaretto D, Marcotte TD, Grant I, Ellis RJ (2006) Valproic acid does not affect markers of HIV disease progression. J Neurovirol 12:403-406
2. Anderson GM (2004) Peripheral and central neurochemical effects of the selective serotonin reuptake inhibitors (SSRIs) in humans and nonhuman primates: assessing bioeffect and mechanisms of action. Int J Dev Neurosci 22:397-404
3. Beck AT, Steer RA, Brown GK (1996) Manual for the Beck Depression Inventory-II. Psychological Corporation, San Antonio, TX
4. Benedict RH (1997) Brief visuospatial memory test - revised. Psychological Assessment Resources, Inc., Odessa, Florida
5. Benedict RH, Schretlen D, Groninger L, Brandt J (1998) Hopkins verbal learning test - revised: normative data and analysis of inter-form and test-retest reliability. Clin Neuropsychol 12:43-55
6. Carey CL, Woods SP, Gonzalez R, Conover E, Marcotte TD, Grant I, Heaton RK (2004) Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. J Clin Exp Neuropsychol 26:307-319
7. Cargill VA, Stone VE (2005) HIV/AIDS: a minority health issue. Med Clin North Am 89:895-912
8. Clifford DB, McArthur JC, Schifitto G, Kieburtz K, McDermott MP, Letendre S, Cohen BA, Marder K, Ellis RJ, Marra CM (2002) A randomized clinical trial of CPI-1189 for HIV-associated cognitive-motor impairment. Neurology 59:1568-1573
9. Currier J, Fliesler N (1995) Demographics of HIV survival revisited. AIDS Clin Care 7:94
10. Cysique LA, Maruff P, Brew BJ (2004) Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras: a combined study of two cohorts. J Neurovirol 10:350-357
11. del Real G, Jimenez-Baranda S, Mira E, Lacalle RA, Lucas P, Gomez-Mouton C, Alegret M, Pena JM, Rodriguez-Zapata M, Alvarez-Mon M, Martinez AC, Manes S (2004) Statins inhibit HIV-1 infection by down-regulating Rho activity. J Exp Med 200:541-547
12. Diehr MC, Heaton RK, Miller W, Grant I (1998) The Paced Auditory Serial Addition Task (PASAT): norms for age, education, and ethnicity. Assessment 5:375-387
13. Dou H, Ellison B, Bradley J, Kasiyanov A, Poluektova LY, Xiong H, Maggirwar S, Dewhurst S, Gelbard HA, Gendelman HE (2005) Neuroprotective mechanisms of lithium in murine human immunodeficiency virus-1 encephalitis. J Neurosci 25:8375-8385
14. Evans RM, Hui S, Perkins A, Lahiri DK, Poirier J, Farlow MR (2004) Cholesterol and APOE genotype interact to influence Alzheimer disease progression. Neurology 62:1869-1871
15. Gallicchio VS, Cibull ML, Hughes NK, Tse KF (1993) Effect of lithium in murine immunodeficiency virus infected animals. Pathobiology 61:216-221
16. Giguere JF, Tremblay MJ (2004) Statin compounds reduce human immunodeficiency virus type 1 replication by preventing the interaction between virion-associated host intercellular adhesion molecule 1 and its natural cell surface ligand LFA-1. J Virol 78:12062-12065
17. Gilbert C, Bergeron M, Methot S, Giguere JF, Tremblay MJ (2005) Statins could be used to control replication of some viruses, including HIV-1. Viral Immunol 18:474-489
18. Gladsjo JA, Schuman CC, Evans JD, Peavy GM, Miller SW, Heaton RK (1999) Norms for letter and category fluency: demographic corrections for age, education, and ethnicity. Assessment 6:147-178
19. Goebel J, Logan B, Forrest K, Mieczkowski A, Roszman TL, Wills-Karp M (2005) Atorvastatin affects interleukin-2 signaling by altering the lipid raft enrichment of the interleukin-2 receptor beta chain. J Investig Med 53:322-328
20. Golden JC (1978) Stroop color and word test. Stoelting Co., Chicago, IL
21. Harvey BH, Meyer CL, Gallichio VS, Manji HK (2002) Lithium salts in AIDS and AIDS-related dementia. Psychopharmacol Bull 36:5-26
22. Heaton RK, Grant I, Matthews CG (1991) Comprehensive norms for an expanded Halstead-Reitan battery: demographic corrections, research findings, and clinical applications. Psychological Assessment Resources, Odessa, FL
23. Heaton RK, Taylor MJ, Manly JJ (2002) Demographic effects and use of demographically corrected norms with the WAIS-III and WMS-III. In: Tulsky D, Saklofske D, Heaton RK, Chelune G, Ivnik R, Bornstein RA, Prifitera A, Ledbetter M (eds) Clinical Interpretation of the WAIS-III and WMS-III. Academic Press, San Diego, CA
24. Heaton RK, Miller SW, Taylor MJ, Grant I (2004a) Revised comprehensive norms for an expanded Halstead-Reitan battery: demographically adjusted neuropsychological norms for African American and Caucasian adults. Psychological Assessment Resources, Lutz, FL
25. Heaton RK, Marcotte TD, Mindt MR, Sadek J, Moore DJ, Bentley H, McCutchan JA, Reicks C, Grant I (2004b) The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc 10:317-331
26. Heseltine PN, Goodkin K, Atkinson JH, Vitiello B, Rochon J, Heaton RK, Eaton EM, Wilkie FL, Sobel E, Brown SJ, Feaster D, Schneider L, Goldschmidts WL, Stover ES (1998) Randomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairment. Arch Neurol 55:41-51
27. Hillyard DZ, Nutt CD, Thomson J, McDonald KJ, Wan RK, Cameron AJ, Mark PB, Jardine AG (2006) Statins inhibit NK cell cytotoxicity by membrane raft depletion rather than inhibition of isoprenylation. Atherosclerosis Jun 27; (Epub ahead of print)
28. Kongs SK, Thompson LL, Iverson GL, Heaton RK (2000) Wisconsin card sorting test-64 card computerized version. Psychological Assessment Resources, Odessa, FL
29. Kristiansen JE, Hansen JB (2000) Inhibition of HIV replication by neuroleptic agents and their potential use in HIV infected patients with AIDS related dementia. Int J Antimicrob Agents 14:209-213
30. Letendre SL, Woods SP, Ellis RJ, Atkinson JH, Masliah E, van den Brande G, Durelle J, Grant I, Everall I (2006) Lithium improves HIV-associated neurocognitive impairment. Aids 20:1885-1888
31. McArthur JC, Haughey N, Gartner S, Conant K, Pardo C, Nath A, Sacktor N (2003) Human immunodeficiency virus-associated dementia: an evolving disease. J Neurovirol 9:205-221
32. Moncunill G, Negredo E, Bosch L, Vilarrasa J, Witvrouw M, Llano A, Clotet B, Este JA (2005) Evaluation of the anti-HIV activity of statins. Aids 19:1697-1700
33. Mukhtar M, Mengistu A, Acheampong E, Sullivan J, Nunnari G, Argyris E, Kalayeh M, Williams K, Pomerantz R (2005) Statins block enhanced transvascular migration of HIV-1-infected cells: a novel therapeutic approach for HIV-1 neuroinvasion (Abstract 391). In: 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA
34. Negredo E, Clotet B, Puig J, Perez-Alvarez N, Ruiz L, Romeu J, Molto J, Rey-Joly C, Blanco J (2006) The effect of atorvastatin treatment on HIV-1-infected patients interrupting antiretroviral therapy. Aids 20:619-621
35. No Authors Listed (1998) A randomized, double-blind, placebo-controlled trial of deprenyl and thioctic acid in human immunodeficiency virus-associated cognitive impairment. Dana consortium on the therapy of HIV dementia and related cognitive disorders. Neurology 50:645-651
36. Palacio H, Kahn JG, Richards TA, Morin SF (2002) Effect of race and/or ethnicity in use of antiretrovirals and prophylaxis for opportunistic infection: a review of the literature. Public Health Rep 117:233-251; discussion 231-232
37. Popik W, Alce TM, Au WC (2002) Human immunodeficiency virus type 1 uses lipid raft-colocalized CD4 and chemokine receptors for productive entry into CD4(+) T cells. J Virol 76:4709-4722
38. Sacktor N (2002) The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. J Neurovirol 8(Suppl 2):115-121
39. Sacktor N, Schifitto G, McDermott MP, Marder K, McArthur JC, Kieburtz K (2000) Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebo-controlled study. Neurology 54:233-235
40. Schifitto G, Sacktor N, Marder K, McDermott MP, McArthur JC, Kieburtz K, Small S, Epstein LG (1999) Randomized trial of the platelet-activating factor antagonist lexipafant in HIV-associated cognitive impairment. Neurological AIDS Research Consortium. Neurology 53:391-396
41. Schifitto G, Peterson DR, Zhong J, Ni H, Cruttenden K, Gaugh M, Gendelman HE, Boska M, Gelbard H (2006) Valproic acid adjunctive therapy for HIV-associated cognitive impairment: a first report. Neurology 66:919-921
42. Schmeer C, Kretz A, Isenmann S (2006) Statin-mediated protective effects in the central nervous system: general mechanisms and putative role of stress proteins. Restor Neurol Neurosci 24: 79-95
43. Tozzi V, Balestra P, Lorenzini P, Bellagamba R, Galgani S, Corpolongo A, Vlassi C, Larussa D, Zaccarelli M, Noto P, Visco-Comandini U, Giulianelli M, Ippolito G, Antinori A, Narciso P (2005) Prevalence and risk factors for human immunodeficiency virus-associated neurocognitive impairment, 1996 to 2002: results from an urban observational cohort. J Neurovirol 11:265-273
44. Valcour VG, Shikuma CM, Shiramizu BT, Williams AE, Watters MR, Poff PW, Grove JS, Selnes OA, Sacktor NC (2005) Diabetes, insulin resistance, and dementia among HIV-1-infected patients. J Acquir Immune Defic Syndr 38:31-36
45. Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM (2003) Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy 23:871-880
46. Zink MC, Uhrlaub J, DeWitt J, Voelker T, Bullock B, Mankowski J, Tarwater P, Clements J, Barber S (2005) Neuroprotective and anti-human immunodeficiency virus activity of minocycline. JAMA 293:2003-2011